跳至主要内容
临床试验/NCT03772028
NCT03772028招募中3 期

Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy

The Netherlands Cancer Institute28 个研究点 分布在 7 个国家目标入组 538 人开始时间: 2020年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
538
试验地点
28
主要终点
overall survival

研究概览

简要总结

stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

详细描述

The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm) with acceptable morbidity, in patients with FIGO stage III epithelial ovarian cancer who are eligible for primary cytoreductive surgery with no residual disease, or residual disease up to 2.5 mm.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • candidate for primary CRS
  • histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer

排除标准

  • history of previous malignancies within 5 years prior to inclusion
  • FIGO stage IV disease
  • complete primary cytoreduction is impossible
  • prior treatment for the current malignancy

研究组 & 干预措施

HIPEC

Experimental

Primary cytoreductive surgery with HIPEC with cisplatin

干预措施: cisplatin (Drug)

结局指标

主要结局

overall survival

时间窗: 1 year after last patient last visit

次要结局

  • recurrence-free survival(1 year after last patient last visit)
  • adverse events(30 days after end of treatment)
  • cost evaluation(1 year after lplv)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (28)

Loading locations...

相似试验